{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:24Z","timestamp":1740107424578,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Charit\u00e9"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Wir schildern den Fall einer 73-j\u00e4hrigen Patientin mit malignem Melanom, die eine rasch progrediente Dermatosklerose der Arme und Beine sowie Myalgien und Beugekontrakturen unter der Therapie mit dem Immuncheckpoint-Inhibitor Nivolumab entwickelte. Bildmorphologisch und bioptisch konnte die Diagnose einer Myofasziitis gesichert werden. Nach R\u00fccksprache mit den behandelnden Dermatoonkologen wurde die Nivolumab-Therapie bei gutem Ansprechen des Malignoms pausiert und eine immunmodulierende Therapie mit Methotrexat und Prednisolon eingeleitet. Immuncheckpointinhibitoren k\u00f6nnen vielf\u00e4ltige immunvermittelte Nebenwirkungen induzieren und auch rheumatologische Krankheitsbilder imitieren. Das Auftreten einer Myofasziitis unter Immuncheckpointinhibition ist nur in wenigen F\u00e4llen in der Literatur berichtet. Sinnvoll f\u00fcr die Diagnostik sind insbesondere die Bestimmung der eosinophilen Leukozyten, eine bildgebende Diagnostik mittels Sonographie und\/oder MRT sowie die Gewinnung einer Gewebebiopsie. Die weitere onkologische und rheumatologische Therapiesteuerung sollte in enger interdisziplin\u00e4rer Abstimmung erfolgen.<\/jats:p>","DOI":"10.1007\/s00393-021-01001-7","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T12:03:30Z","timestamp":1619093010000},"page":"884-888","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Myofasziitis unter Nivolumab-Therapie","Myofasciitis under nivolumab treatment"],"prefix":"10.1007","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0582-7790","authenticated-orcid":false,"given":"M.","family":"Krusche","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Stenzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ohrndorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"issue":"8","key":"1001_CR1","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1007\/s00393-020-00870-8","volume":"79","author":"C Lamos","year":"2020","unstructured":"Lamos\u00a0C, Hunger\u00a0RE (2020) Checkpoint-Inhibitoren \u2013 Indikation und Verwendung bei Melanompatienten. Z\u00a0Rheumatol 79(8):818\u2013825","journal-title":"Z Rheumatol"},{"key":"1001_CR2","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2019.0497","author":"P Terheyden","year":"2019","unstructured":"Terheyden\u00a0P, Krackhardt\u00a0A, Eigentler\u00a0T (2019) The systemic treatment of melanoma. Dtsch Aerztebl. https:\/\/doi.org\/10.3238\/arztebl.2019.0497","journal-title":"Dtsch Aerztebl"},{"issue":"1","key":"1001_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals\u00a0M, Brahmer\u00a0JR, Callahan\u00a0MK, Flores-Ch\u00e1vez\u00a0A, Keegan\u00a0N, Khamashta\u00a0MA et al (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 6(1):38","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"1001_CR4","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s00393-020-00873-5","volume":"79","author":"SH Verspohl","year":"2020","unstructured":"Verspohl\u00a0SH, Schulze-Koops\u00a0H, Heine\u00a0A, Sch\u00e4fer\u00a0VS (2020) Pr\u00e4valenz und Therapie von rheumatologischen Nebenwirkungen bei Immun-Checkpoint-Inhibitor-Therapie. Z\u00a0Rheumatol 79(8):797\u2013808","journal-title":"Z Rheumatol"},{"issue":"3","key":"1001_CR5","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/art.40745","volume":"71","author":"MD Richter","year":"2019","unstructured":"Richter\u00a0MD, Crowson\u00a0C, Kottschade\u00a0LA, Finnes\u00a0HD, Markovic\u00a0SN, Thanarajasingam\u00a0U (2019) Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients. Arthritis Rheumatol 71(3):468\u2013475","journal-title":"Arthritis Rheumatol"},{"key":"1001_CR6","first-page":"607","volume":"78","author":"M Ramos-Casals","year":"2019","unstructured":"Ramos-Casals\u00a0M, Lambotte\u00a0O, Kostine\u00a0M et al (2019) Thu0628 immune-related adverse events induced by cancer immunotherapies. Big data analysis of 13,051 cases (Immunocancer international registry). Ann Rheum Dis 78:607\u2013608","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1001_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-019-03273-1","volume":"145","author":"K Sato","year":"2019","unstructured":"Sato\u00a0K, Mano\u00a0T, Iwata\u00a0A, Toda\u00a0T (2019) Neurological and related adverse events in immune checkpoint inhibitors: a\u00a0pharmacovigilance study from the Japanese Adverse Drug Event Report database. J\u00a0Neurooncol 145(1):1\u20139","journal-title":"J Neurooncol"},{"issue":"11","key":"1001_CR8","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki\u00a0S, Ishikawa\u00a0N, Konoeda\u00a0F, Seki\u00a0N, Fukushima\u00a0S, Takahashi\u00a0K et al (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89(11):1127\u20131134","journal-title":"Neurology"},{"issue":"7","key":"1001_CR9","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1016\/j.jtho.2017.02.024","volume":"12","author":"RYC Tan","year":"2017","unstructured":"Tan\u00a0RYC, Toh\u00a0CK, Takano\u00a0A (2017) Continued response to one dose of nivolumab complicated by myasthenic crisis and Myositis. J\u00a0Thorac Oncol 12(7):e90\u2013e91","journal-title":"J Thorac Oncol"},{"issue":"10","key":"1001_CR10","doi-asserted-by":"publisher","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","volume":"91","author":"M Touat","year":"2018","unstructured":"Touat\u00a0M, Maisonobe\u00a0T, Knauss\u00a0S, Hadj Salem\u00a0BO, Hervier\u00a0B, Aur\u00e9\u00a0K et al (2018) Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 91(10):e985\u2013e994","journal-title":"Neurology"},{"issue":"1","key":"1001_CR11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","volume":"80","author":"M Kostine","year":"2021","unstructured":"Kostine\u00a0M, Finckh\u00a0A, Bingham\u00a0CO, Visser\u00a0K, Leipe\u00a0J, Schulze-Koops\u00a0H et al (2021) EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis 80(1):36\u201348","journal-title":"Ann Rheum Dis"},{"key":"1001_CR12","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0508","author":"KK Chan","year":"2019","unstructured":"Chan KK, Magro C, Shoushtari A, Rudin C, Rotemberg V, Rossi A et\u00a0al (2019) Eosinophilic fasciitis following checkpoint inhibitor therapy: four cases and a\u00a0review of literature. Oncologist. https:\/\/doi.org\/10.1634\/theoncologist.2019-0508","journal-title":"Oncologist"},{"issue":"1","key":"1001_CR13","doi-asserted-by":"publisher","first-page":"1727116","DOI":"10.1080\/2162402X.2020.1727116","volume":"9","author":"SCS Simon","year":"2020","unstructured":"Simon\u00a0SCS, Hu\u00a0X, Panten\u00a0J, Grees\u00a0M, Renders\u00a0S, Thomas\u00a0D et\u00a0al (2020) Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors. OncoImmunology 9(1):1727116","journal-title":"OncoImmunology"},{"issue":"4","key":"1001_CR14","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s40744-020-00246-z","volume":"7","author":"C Salamaliki","year":"2020","unstructured":"Salamaliki\u00a0C, Solomou\u00a0EE, Liossis\u00a0S\u2011NC (2020) Immune checkpoint inhibitor-associated scleroderma-like syndrome: a report of a\u00a0pembrolizumab-induced \u201cEosinophilic Fasciitis-like\u201d case and a\u00a0review of the literature. Rheumatol Ther 7(4):1045\u20131052","journal-title":"Rheumatol Ther"},{"issue":"12","key":"1001_CR15","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1111\/imj.14126","volume":"48","author":"A Rischin","year":"2018","unstructured":"Rischin\u00a0A, Brady\u00a0B, McLean\u00a0C, Ostor\u00a0AJK (2018) Immune checkpoint inhibitor-induced lymphocytic fasciitis. Intern Med\u00a0J 48(12):1550\u20131552","journal-title":"Intern Med J"},{"issue":"12","key":"1001_CR16","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1093\/rheumatology\/kex369","volume":"56","author":"D Daoussis","year":"2017","unstructured":"Daoussis\u00a0D, Kraniotis\u00a0P, Liossis\u00a0S\u2011N, Solomou\u00a0A (2017) Immune checkpoint inhibitor-induced myo-fasciitis. Rheumatology 56(12):2161\u20132161","journal-title":"Rheumatology"},{"issue":"Supplement_7","key":"1001_CR17","doi-asserted-by":"publisher","first-page":"vii49","DOI":"10.1093\/rheumatology\/kez360","volume":"58","author":"J Leipe","year":"2019","unstructured":"Leipe\u00a0J, Mariette\u00a0X (2019) Management of rheumatic complications of ICI therapy: a\u00a0rheumatology viewpoint. Rheumatology 58(Supplement_7):vii49\u201358","journal-title":"Rheumatology"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-021-01001-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-021-01001-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-021-01001-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T14:03:15Z","timestamp":1636380195000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-021-01001-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1001"],"URL":"https:\/\/doi.org\/10.1007\/s00393-021-01001-7","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2021,4,22]]},"assertion":[{"value":"25 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Krusche, U.\u00a0Schneider, C.\u00a0Geisler, S.\u00a0Keller, W.\u00a0Stenzel und S.\u00a0Ohrndorf geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}